Stockscreener 앱 받기
4.19
3.46%
-0.15
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at B. Riley - Defense World
B. Riley Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Strong-Buy" - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at B. Riley - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. Riley - MarketBeat
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology - Seeking Alpha
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target -January 30, 2025 at 07:56 am EST - Marketscreener.com
Foghorn Therapeutics receives Nasdaq compliance notice - MSN
Foghorn Therapeutics receives Nasdaq compliance notice By Investing.com - Investing.com Australia
Foghorn Therapeutics (FHTX) Stock Price, News & Analysis - MarketBeat
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Jane Street Group LLC - Defense World
Foghorn Therapeutics Sets 2025 Strategic Objectives - TipRanks
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 - The Manila Times
Foghorn Therapeutics Advances Cancer Drug Pipeline, Secures Runway into 2027 with $243.8M Cash - StockTitan
Barclays PLC Acquires 26,228 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLC - Defense World
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Expands By 6.8% - MarketBeat
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41% - Simply Wall St
Foghorn Therapeutics announces director resignation - Investing.com India
Foghorn Therapeutics announces director resignation By Investing.com - Investing.com Nigeria
Foghorn Therapeutics Board Member Resignation Announced - TipRanks
State Street Corp Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - Asianet Newsable
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
3.95%
2.39%
자본화:
|
볼륨(24시간):